A prospective observational multicenter study.
To help solve the debate regarding whether the anterior or posterior surgical approach is optimal for patients with cervical spondylotic myelopathy
Summary of Background Data.
The optimal surgical approach to treat CSM
remains debated with varying opinions favoring anterior versus
posterior surgical approaches. We present an analysis of a prospective observational multicenter study examining outcomes of surgical treatment for CSM
A total of 278 subjects from 12 sites in North America received anterior/posterior or combined surgery
at the discretion of the surgeon. This study focused on subjects who had either anterior or posterior surgery
(n = 264, follow-up rate, 87%). Outcome measures included the modified Japanese Orthopedic Assessment scale, the Nurick scale, the Neck Disability Index, and the Short-Form 36 (SF-36) Health Survey version 2 Physical and Mental Component Scores.
One hundred and sixty-nine patients were treated anteriorly and 95 underwent posterior surgery
. Anterior surgical cases were younger and had less severe myelopathy as assessed by mJOA and Nurick scores. There were no baseline differences in Neck Disability Index or SF-36 between the anterior and posterior cases. Improvement in the mJOA was significantly lower in the anterior group than posterior group (2.47 vs
. 3.62, respectively, P
< 0.01), although the groups started at different levels of baseline impairment. The extent of improvement in the Nurick Scale, Neck Disability Index, SF-36 version 2 Physical Component Score, and SF-36 version 2 Mental Component Score did not differ between the groups.
Patients with CSM
show significant improvements in several health-related outcome measures with either anterior or posterior surgery
. Importantly, patients treated with anterior techniques were younger, with less severe impairment and more focal pathology. We demonstrate for the first time that, when patient and disease factors are controlled for, anterior and posterior surgical techniques have equivalent efficacy in the treatment of CSM
Level of Evidence: 3